Paxlovid Tied to Benefits in High-Risk Patients With COVID

The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit.
Medscape Medical News